Investment Thesis
Anika Therapeutics exhibits strong balance sheet fundamentals with excellent liquidity (4.72x current ratio) and conservative leverage (0.17x debt/equity), but faces operational headwinds with negative operating margins (-9.8%) and declining revenue (-5.9% YoY). The company is generating positive free cash flow ($4.4M) despite net losses, suggesting operational improvements may be emerging, though profitability recovery remains uncertain.
ANIK Strengths
- Exceptional liquidity position with $57.5M cash and 4.72x current ratio provides significant financial flexibility
- Strong balance sheet with moderate leverage (0.17x D/E) and $143.5M stockholders' equity
- Positive free cash flow generation ($4.4M) despite GAAP losses indicates underlying operational cash generation
- Substantial gross margin of 56.6% demonstrates healthy product economics and pricing power
ANIK Risks
- Persistent profitability challenges with negative operating (-9.8%) and net margins (-9.6%)
- Revenue contraction of 5.9% YoY signals demand pressure or market share loss
- Operating losses of $11.1M are not offset by strong cash generation, suggesting one-time charges or non-cash impacts
- Medical devices sector experiencing competitive pressure; company's turnaround path unclear
Key Metrics to Watch
- Revenue growth trajectory and segment performance - must stabilize and return to growth
- Operating margin progression - path to positive EBIT is critical for valuation
- Cash burn rate and free cash flow sustainability - ensure runway extends beyond turnaround period
- Gross margin stability - monitor for pricing pressure or unfavorable product mix shifts
ANIK Financial Metrics
ANIK Profitability Ratios
ANIK Balance Sheet & Liquidity
ANIK 5-Year Financial Trend
5-Year Trend Summary: Anika Therapeutics, Inc.'s revenue has declined by 18% over the 5-year period, indicating business contraction. The most recent EPS of $-5.64 indicates the company is currently unprofitable.
ANIK Growth Metrics (YoY)
ANIK Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $27.8M | -$88.0K | $-0.16 |
| Q2 2025 | $28.2M | -$88.0K | $0.00 |
| Q1 2025 | $26.2M | -$4.5M | $-0.31 |
| Q3 2024 | $38.8M | -$88.0K | $-0.45 |
| Q2 2024 | $41.9M | -$88.0K | $-0.01 |
| Q1 2024 | $37.9M | -$4.5M | $-0.31 |
| Q3 2023 | $40.3M | -$2.7M | $-0.29 |
| Q2 2023 | $39.7M | -$2.7M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ANIK Capital Allocation
ANIK SEC Filings
Access official SEC EDGAR filings for Anika Therapeutics, Inc. (CIK: 0000898437)